# Congenital hyperinsulinism in an individual with CHARGE syndrome and a pathogenic CHD7 variant

**Authors:** Consuelo Ibeas, Franco Giraudo, Jonna M E Männistö, Sarah E Flanagan, Verónica Mericq

PMC · DOI: 10.1210/jcemcr/luag016 · JCEM Case Reports · 2026-02-24

## TL;DR

A rare case of neonatal hyperinsulinemic hypoglycemia is reported in a patient with CHARGE syndrome caused by a CHD7 gene variant.

## Contribution

This case expands the clinical spectrum of CHARGE syndrome by linking a CHD7 variant to hyperinsulinemic hypoglycemia.

## Key findings

- A Chilean female with CHARGE syndrome and a CHD7 variant presented with neonatal hyperinsulinemic hypoglycemia.
- No pathogenic variants in 22 known HI-associated genes were found, suggesting a link between CHD7 and HI.
- The patient responded well to diazoxide treatment for glucose management.

## Abstract

Hyperinsulinemic hypoglycemia (HI) is a rare feature in individuals with coloboma, heart defects, atresia choanae, retardation of growth and development, genital abnormalities, and ear abnormalities (CHARGE) syndrome, though its underlying mechanisms remain poorly understood. We report a Chilean female proband with genetically confirmed CHARGE syndrome caused by a pathogenic variant in the CHD7 gene, who presented with HI in the neonatal period. Initial hypoglycemia was detected on days 2-3 of life, followed by recurrent episodes prompting biochemical investigation. On day 21, HI was biochemically confirmed. Comprehensive hormonal evaluation, including cortisol and growth hormone testing, excluded deficiencies in these hormones as contributing factors. Genetic screening of 22 known HI-associated genes revealed no pathogenic variants, supporting the hypothesis that HI in this case is related to CHARGE syndrome rather than being a coincidental finding. The patient responded well to diazoxide treatment, which allowed for maintenance of normoglycemia, with gradual dose reduction as glucose management normalized. This case, along with 2 previously reported cases, suggests that HI can be an integral part of CHARGE syndrome. Further research is needed to understand the mechanisms connecting CHD7 variants and HI and to refine management strategies for affected individuals.

## Linked entities

- **Genes:** CHD7 (chromodomain helicase DNA binding protein 7) [NCBI Gene 55636]
- **Chemicals:** diazoxide (PubChem CID 3019)
- **Diseases:** CHARGE syndrome (MONDO:0008965), hyperinsulinemic hypoglycemia (MONDO:0005803)

## Full-text entities

- **Genes:** AKT2 (AKT serine/threonine kinase 2) [NCBI Gene 208] {aka HIHGHH, PKBB, PKBBETA, PRKBB, RAC-BETA}, GCG (glucagon) [NCBI Gene 2641] {aka GLP-1, GLP1, GLP2, GRPP}, FOXA2 (forkhead box A2) [NCBI Gene 3170] {aka HNF-3-beta, HNF3B, TCF3B}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, GLUD1 (glutamate dehydrogenase 1) [NCBI Gene 2746] {aka GDH, GDH1, GLUD, hGDH1}, EP300 (EP300 lysine acetyltransferase) [NCBI Gene 2033] {aka KAT3B, MKHK2, RSTS2, p300}, ABCC8 (ATP binding cassette subfamily C member 8) [NCBI Gene 6833] {aka ABC36, HHF1, HI, HRINS, MODY12, MRP8}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, KCNJ11 (potassium inwardly rectifying channel subfamily J member 11) [NCBI Gene 3767] {aka BIR, HHF2, IKATP, KIR6.2, MODY13, PHHI}, HNF1A (HNF1 homeobox A) [NCBI Gene 6927] {aka HNF-1-alpha, HNF-1A, HNF1, HNF1alpha, IDDM20, LFB1}, NSD1 (nuclear receptor binding SET domain protein 1) [NCBI Gene 64324] {aka ARA267, KMT3B, SOTOS, SOTOS1, STO}, CREBBP (CREB binding lysine acetyltransferase) [NCBI Gene 1387] {aka CBP, KAT3A, MKHK1, RSTS, RSTS1}, KDM6A (lysine demethylase 6A) [NCBI Gene 7403] {aka KABUK2, UTX, bA386N14.2}, PMM2 (phosphomannomutase 2) [NCBI Gene 5373] {aka CDG1, CDG1a, CDGS, PMI, PMI1, PMM 2}, GH1 (growth hormone 1) [NCBI Gene 2688] {aka GH, GH-N, GHB5, GHN, IGHD1A, IGHD1B}, MAFA (MAF bZIP transcription factor A) [NCBI Gene 389692] {aka INSDM, RIPE3b1, hMafA}, SLC16A1 (solute carrier family 16 member 1) [NCBI Gene 6566] {aka HHF7, MCT, MCT1, MCT1D}, IGFBP3 (insulin like growth factor binding protein 3) [NCBI Gene 3486] {aka BP-53, IBP-3, IBP3, IGFBP-3}, GGH (gamma-glutamyl hydrolase) [NCBI Gene 8836] {aka GATD10, GH}, GPC3 (glypican 3) [NCBI Gene 2719] {aka DGSX, GTR2-2, MXR7, OCI-5, SDYS, SGB}, HNF4A (hepatocyte nuclear factor 4 alpha) [NCBI Gene 3172] {aka FRTS4, HNF4, HNF4a7, HNF4a8, HNF4a9, HNF4alpha}, POMC (proopiomelanocortin) [NCBI Gene 5443] {aka ACTH, CLIP, LPH, MSH, NPP, OBAIRH}, KMT2D (lysine methyltransferase 2D) [NCBI Gene 8085] {aka AAD10, ALR, BCAHH, CAGL114, KABUK1, KMS}, CACNA1D (calcium voltage-gated channel subunit alpha1 D) [NCBI Gene 776] {aka CACH3, CACN4, CACNL1A2, CCHL1A2, Cav1.3, PASNA}, HADH (hydroxyacyl-CoA dehydrogenase) [NCBI Gene 3033] {aka HAD, HADH1, HADHSC, HCDH, HHF4, MSCHAD}, GCK (glucokinase) [NCBI Gene 2645] {aka FGQTL3, GK, GLK, HHF3, HK4, HKIV}, INSR (insulin receptor) [NCBI Gene 3643] {aka CD220, HHF5}, CHD7 (chromodomain helicase DNA binding protein 7) [NCBI Gene 55636] {aka CRG, HH5, IS3, KAL5}, TRMT10A (tRNA methyltransferase 10A) [NCBI Gene 93587] {aka HEL-S-88, MSSGM, MSSGM1, RG9MTD2, TRM10}, PHOX2B (paired like homeobox 2B) [NCBI Gene 8929] {aka CCHS, NBLST2, NBPhox, PMX2B}
- **Diseases:** heart defects (MESH:D006330), trisomy 21 (MESH:D004314), patent ductus arteriosus (MESH:D004374), endocrine disorders (MESH:D004700), ear abnormalities (MESH:D004427), adrenal insufficiency (MESH:D000309), optic nerve coloboma (MESH:C535970), HI (MESH:D007003), growth deficiency (MESH:D006130), brain anomalies (MESH:D001927), hyperinsulinism (MESH:D006946), suppressed ketogenesis (MESH:D000550), Congenital hyperinsulinism (MESH:D044903), dysfunction of the hypothalamic-pituitary-adrenal axis (MESH:D007027), Kabuki syndrome (MESH:C537705), Beckwith-Wiedemann syndrome (MESH:D001506), congenital anomalies (MESH:D000013), pituitary dysfunction (MESH:D010900), nervous system abnormalities (MESH:D009421), critical illness (MESH:D016638), swallowing impairments (MESH:D003680), subdural hygromas (MESH:D013353), cranial nerve dysfunction (MESH:D003389), CHD7 disorder (MESH:D009358), GH deficiency (MESH:D004393), coloboma (MESH:D003103), left orbicularis hypoplasia (MESH:D018636), CHARGE syndrome (MESH:D058747), developmental delay (MESH:D002658), cochlear opening stenosis (MESH:D003251), Ebstein anomaly (MESH:D004437), sensorineural hearing loss (MESH:D006319), inappropriate insulin secretion (MESH:D006966), atresia choanae (MESH:D018633), pituitary anomalies (MESH:C566440), gestational diabetes (MESH:D016640), thalamic infarction (MESH:D007238), genital abnormalities (MESH:D014564), Platybasia (MESH:D010985), hypertrichosis (MESH:D006983), subdural hematomas (MESH:D006408)
- **Chemicals:** ketones (MESH:D007659), acylcarnitine (MESH:C116917), cortisol (MESH:D006854), amino acid (MESH:D000596), ammonium (MESH:D064751), thyroxine (MESH:D013974), FT4 (-), blood glucose (MESH:D001786), Glucose (MESH:D005947), Diazoxide (MESH:D003981)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** p.Arg2627a, c.7879C>T, p.Arg2627*

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12930190/full.md

## References

17 references — full list in the complete paper: https://tomesphere.com/paper/PMC12930190/full.md

---
Source: https://tomesphere.com/paper/PMC12930190